Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04809662 · ClinicalTrials.gov registry record
Comparing Immune Responses to Topical Imiquimod
A clinical trial, sponsored by University of California, Davis.
- Terminated
- Registry status
- 6
- Enrollment target
NCT04809662 is a clinical trial that was terminated before completion, run by University of California, Davis. The registered enrollment target is 6 participants.
The verdict
NCT04809662 was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after application of topical imiquimod to these patients.
Interventions
- DRUG Imiquimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2023-11-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04809662
The ClinicalTrials.gov registry entry for NCT04809662 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imiquimod is the first listed.
NCT04809662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04809662 about?
NCT04809662 is a clinical study titled "Comparing Immune Responses to Topical Imiquimod". The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after applicati...
What is the current status of trial NCT04809662?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2021-03-16. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT04809662?
The interventions under investigation include: Imiquimod (DRUG).
Who is sponsoring clinical trial NCT04809662?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.